Xing Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xing Zhang has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Baojin Hua
Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
5 shared publications - Qiujun Guo
Guang’anmen Hospital, China Academy of Chinese Medical Sciences
3 shared publications - Bo Pang
Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China
2 shared publications Fudong Liu
Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
2 shared publicationsJuling Jiang
Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
2 shared publications- Runzhi Qi
Department of Oncology, Academy of Chinese Medical Sciences, Guang’anmen Hospital, China , Beijing, China
2 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by KEAI Publishing in Bioactive Materials
- Vol. 67, 719-739
Metabolic targeting by a small extracellular vesicle-based cellulose-GelMA hydrogel restores neurovascular regeneration in diabetic nerve injury
- 1 January 2027
- Published by KEAI Publishing in Bioactive Materials
- Vol. 67, 719-739
Open AccessMetabolic targeting by a small extracellular vesicle-based cellulose-GelMA hydrogel restores neurovascular regeneration in diabetic nerve injury
- Open Access
- 29 October 2026
- Published by Springer Nature in Stem Cell Research & Therapy
Netrin-1 enriched ADSC exosomes attenuate abdominal aortic aneurysm via NF-κB and JNK/AP-1 modulation
Background: Abdominal aortic aneurysm (AAA) is a macrophage-driven disease without effective pharmacological therapy. Given the anti-inflammatory effects of Netrin-1 in macrophages, this study aimed to investigate whether exosomes derived from Netrin-1 overexpressing adipose-derived stem cells (N-ADSC-exo) can reprogram macrophages and attenuate AAA. Methods: Murine ADSCs were transduced with or without Netrin-1 adenoviral vectors to generate ADSC-exo and N-ADSC-exo. Effects on RAW264.7 macrophages were evaluated by adhesion and migration assays, LPS-induced ROS, apoptosis, and CCK-8 viability. Bulk RNA sequencing with GO/KEGG enrichment and GSEA compared transcriptomes. NF-κB and JNK/AP-1 signaling and polarization markers were analyzed by Western blotting. In ApoE −/− mice with Ang II-induced AAA, PBS, ADSC-exo, or N-ADSC-exo were injected intravenously. AAA incidence, maximal abdominal aortic diameter, elastin/collagen histology, immunofluorescence analysis of macrophage polarization, aortic IL-1β/MMP9, DiD-labeled exosome biodistribution, and systemic biocompatibility were assessed. Results: ADSC-exo and N-ADSC-exo were similarly internalized by macrophages. Compared with ADSC-exo, N-ADSC-exo enhanced adhesion and migration, reduced LPS-induced ROS without increasing apoptosis, and modestly increased viability. RNA sequencing showed enrichment of cell-cycle pathways and suppression of NF-κB related gene sets in N-ADSC-exo treated cells, consistent at the protein level with decreased p-p65, p-JNK, AP-1 and IL-1β, and increased M2 markers. In AAA mice, N-ADSC-exo showed preferential uptake by F4/80 + cells, lowered AAA incidence, reduced aortic diameter, improved elastin preservation, decreased F4/80 + CD86 + macrophages and IL-1β/MMP9, and did not induce systemic toxicity. Conclusions: N-ADSC-exo mitigate AAA via macrophage reprogramming toward a NF-κB and JNK/AP-1 suppressed, M2-skewed phenotype.
- 29 October 2026
- Published by Springer Nature in Stem Cell Research & Therapy
Open AccessNetrin-1 enriched ADSC exosomes attenuate abdominal aortic aneurysm via NF-κB and JNK/AP-1 modulation
Background: Abdominal aortic aneurysm (AAA) is a macrophage-driven disease without effective pharmacological therapy. Given the anti-inflammatory effects of Netrin-1 in macrophages, this study aimed to investigate whether exosomes derived from Netrin-1 overexpressing adipose-derived stem cells (N-ADSC-exo) can reprogram macrophages and attenuate AAA. Methods: Murine ADSCs were transduced with or without Netrin-1 adenoviral vectors to generate ADSC-exo and N-ADSC-exo. Effects on RAW264.7 macrophages were evaluated by adhesion and migration assays, LPS-induced ROS, apoptosis, and CCK-8 viability. Bulk RNA sequencing with GO/KEGG enrichment and GSEA compared transcriptomes. NF-κB and JNK/AP-1 signaling and polarization markers were analyzed by Western blotting. In ApoE −/− mice with Ang II-induced AAA, PBS, ADSC-exo, or N-ADSC-exo were injected intravenously. AAA incidence, maximal abdominal aortic diameter, elastin/collagen histology, immunofluorescence analysis of macrophage polarization, aortic IL-1β/MMP9, DiD-labeled exosome biodistribution, and systemic biocompatibility were assessed. Results: ADSC-exo and N-ADSC-exo were similarly internalized by macrophages. Compared with ADSC-exo, N-ADSC-exo enhanced adhesion and migration, reduced LPS-induced ROS without increasing apoptosis, and modestly increased viability. RNA sequencing showed enrichment of cell-cycle pathways and suppression of NF-κB related gene sets in N-ADSC-exo treated cells, consistent at the protein level with decreased p-p65, p-JNK, AP-1 and IL-1β, and increased M2 markers. In AAA mice, N-ADSC-exo showed preferential uptake by F4/80 + cells, lowered AAA incidence, reduced aortic diameter, improved elastin preservation, decreased F4/80 + CD86 + macrophages and IL-1β/MMP9, and did not induce systemic toxicity. Conclusions: N-ADSC-exo mitigate AAA via macrophage reprogramming toward a NF-κB and JNK/AP-1 suppressed, M2-skewed phenotype.
- Top Cited Papers
- 27 March 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (7) , e327592
FOXO1 Integrates Endothelial Hemodynamic, Inflammatory, and Metabolic Pathways in Atherosclerosis
BACKGROUND: Atherosclerosis occurs preferentially in regions of disturbed fluid shear stress (FSS), whereas physiological laminar FSS protects against disease by suppressing endothelial inflammation. Proinflammatory versus anti-inflammatory programs are associated with glycolysis versus oxidative phosphorylation, respectively, but mechanisms are poorly understood. The TF (transcription factor) FOXO1 (forkhead box protein O1) is known to regulate endothelial metabolism and angiogenesis, but little is known about its role in endothelial inflammation. METHODS: Endothelial cells were treated with cytokines or subjected to defined flow patterns in vitro using a parallel plate flow chamber. Immunofluorescence, RNA sequencing, and biochemical assays assessed FOXO1 localization, gene expression, and posttranslational modifications. In vivo experiments used FOXO1-floxed mice crossed with Bmx-CreER T2 (bone marrow kinase on chromosome X- Cre recombinase estrogen receptor fusion) for artery endothelial cell–specific FOXO1 knockout. Hyperlipidemia was induced via injection of PCSK9 (proprotein convertase subtilisin/kexin type 9) adeno-associated virus and high-cholesterol/high-fat diet to assess atherosclerosis. RESULTS: Oscillatory FSS and inflammatory cytokines induced whereas physiological FSS inhibited FOXO1 nuclear translocation. Depleting FOXO1 in endothelial cells upregulated the protective flow-responsive TFs KLF2/4 (Krüppel-like factor 2 and 44) and reduced oscillatory FSS-induced inflammatory genes. Inhibition of FOXO1 nuclear translocation by physiological FSS is mediated via a KLF2-CDK2 (cell cycle–dependent kinase 2) pathway, with the latter phosphorylating FOXO1 at S249 (Serine 249). Artery endothelial cell–specific deletion of FOXO1 significantly reduced atherosclerotic plaques in hyperlipidemic mice. Inhibition of glycolysis blocked oscillatory shear stress–induced FOXO1 nucleus translocation, while treatment with lactate promoted FOXO1 nuclear localization. These effects required lactyltransferase AARS1 (alanyl-tRNA synthetase 1) and correlated with FOXO1 lactylation. CONCLUSIONS: These findings identify FOXO1 as a key mediator linking atheroprone flow and endothelial inflammatory gene expression via lactate-driven lactylation and nuclear translocation, promoting atherosclerosis. Conversely, physiological FSS suppresses FOXO1 via KLF2-CDK2 signaling. These complementary pathways suggest potential new therapeutic targets for treating atherosclerotic cardiovascular disease.
- 27 March 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (7) , e327592
Top Cited PapersFOXO1 Integrates Endothelial Hemodynamic, Inflammatory, and Metabolic Pathways in Atherosclerosis
BACKGROUND: Atherosclerosis occurs preferentially in regions of disturbed fluid shear stress (FSS), whereas physiological laminar FSS protects against disease by suppressing endothelial inflammation. Proinflammatory versus anti-inflammatory programs are associated with glycolysis versus oxidative phosphorylation, respectively, but mechanisms are poorly understood. The TF (transcription factor) FOXO1 (forkhead box protein O1) is known to regulate endothelial metabolism and angiogenesis, but little is known about its role in endothelial inflammation. METHODS: Endothelial cells were treated with cytokines or subjected to defined flow patterns in vitro using a parallel plate flow chamber. Immunofluorescence, RNA sequencing, and biochemical assays assessed FOXO1 localization, gene expression, and posttranslational modifications. In vivo experiments used FOXO1-floxed mice crossed with Bmx-CreER T2 (bone marrow kinase on chromosome X- Cre recombinase estrogen receptor fusion) for artery endothelial cell–specific FOXO1 knockout. Hyperlipidemia was induced via injection of PCSK9 (proprotein convertase subtilisin/kexin type 9) adeno-associated virus and high-cholesterol/high-fat diet to assess atherosclerosis. RESULTS: Oscillatory FSS and inflammatory cytokines induced whereas physiological FSS inhibited FOXO1 nuclear translocation. Depleting FOXO1 in endothelial cells upregulated the protective flow-responsive TFs KLF2/4 (Krüppel-like factor 2 and 44) and reduced oscillatory FSS-induced inflammatory genes. Inhibition of FOXO1 nuclear translocation by physiological FSS is mediated via a KLF2-CDK2 (cell cycle–dependent kinase 2) pathway, with the latter phosphorylating FOXO1 at S249 (Serine 249). Artery endothelial cell–specific deletion of FOXO1 significantly reduced atherosclerotic plaques in hyperlipidemic mice. Inhibition of glycolysis blocked oscillatory shear stress–induced FOXO1 nucleus translocation, while treatment with lactate promoted FOXO1 nuclear localization. These effects required lactyltransferase AARS1 (alanyl-tRNA synthetase 1) and correlated with FOXO1 lactylation. CONCLUSIONS: These findings identify FOXO1 as a key mediator linking atheroprone flow and endothelial inflammatory gene expression via lactate-driven lactylation and nuclear translocation, promoting atherosclerosis. Conversely, physiological FSS suppresses FOXO1 via KLF2-CDK2 signaling. These complementary pathways suggest potential new therapeutic targets for treating atherosclerotic cardiovascular disease.
- 20 December 2025
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 83 (5) , 1318-1330.e3
Three-branched in situ laser fenestration for the endovascular repair of total aortic arch disease: A retrospective analysis of 5-year outcomes
- 20 December 2025
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 83 (5) , 1318-1330.e3
Three-branched in situ laser fenestration for the endovascular repair of total aortic arch disease: A retrospective analysis of 5-year outcomes
- Open Access
- 12 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (37) , e41820
Bidirectional Mendelian randomization and immune cell mediation analysis: A STROBE-MR study unveiling the causal link between non-small cell and small cell lung cancers
A certain number of non-small cell lung cancer (NSCLC) transform into small cell lung cancer (SCLC) during treatment, presenting a poorer prognosis compared to the original tumor. However, the causal association between NSCLC and SCLC remains uncertain. We utilized Mendelian randomization (MR) and colocalization analysis to investigate potential causal relationships between NSCLC and SCLC. Additionally, we employed mediation analysis to assess the mediating effect of immune cells on the causal relationship between squamous cell carcinoma (LUSC) and SCLC. Summary data on lung cancer subtypes and immune cells were obtained from comprehensive genetic databases FinnGen, TRICL and GWAS catalog. Our findings suggest a strong causal relationship between NSCLC and SCLC (OR = 2.20, 95% CI = 1.32–3.69, P -value < .01), specifically between LUSC and SCLC (OR = 1.98, 95% CI = 1.23–3.19, P -value < .01). Mediation analysis showed that LUSC had a causal effect on 26 subsets of immune cells, while CD25 on IgD − CD38 − B cell had a reverse causal relationship with SCLC (OR = 0.732, 95% CI = 0.602–0.891, P = .002). Colocalization and annotation analysis highlighted BRCA2, CYP2A6, and CHRNA3 as shared causal genes of LUSC on SCLC. This genetic association study provided evidence of a causal relationship between NSCLC (specifically LUSC) and SCLC, emphasizing the importance of genetic factors and the need for routine genetic profiling in clinical practice, while also highlighting the necessity for further research to understand the underlying mechanisms for developing more effective therapies.
- 12 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (37) , e41820
Open AccessBidirectional Mendelian randomization and immune cell mediation analysis: A STROBE-MR study unveiling the causal link between non-small cell and small cell lung cancers
A certain number of non-small cell lung cancer (NSCLC) transform into small cell lung cancer (SCLC) during treatment, presenting a poorer prognosis compared to the original tumor. However, the causal association between NSCLC and SCLC remains uncertain. We utilized Mendelian randomization (MR) and colocalization analysis to investigate potential causal relationships between NSCLC and SCLC. Additionally, we employed mediation analysis to assess the mediating effect of immune cells on the causal relationship between squamous cell carcinoma (LUSC) and SCLC. Summary data on lung cancer subtypes and immune cells were obtained from comprehensive genetic databases FinnGen, TRICL and GWAS catalog. Our findings suggest a strong causal relationship between NSCLC and SCLC (OR = 2.20, 95% CI = 1.32–3.69, P -value < .01), specifically between LUSC and SCLC (OR = 1.98, 95% CI = 1.23–3.19, P -value < .01). Mediation analysis showed that LUSC had a causal effect on 26 subsets of immune cells, while CD25 on IgD − CD38 − B cell had a reverse causal relationship with SCLC (OR = 0.732, 95% CI = 0.602–0.891, P = .002). Colocalization and annotation analysis highlighted BRCA2, CYP2A6, and CHRNA3 as shared causal genes of LUSC on SCLC. This genetic association study provided evidence of a causal relationship between NSCLC (specifically LUSC) and SCLC, emphasizing the importance of genetic factors and the need for routine genetic profiling in clinical practice, while also highlighting the necessity for further research to understand the underlying mechanisms for developing more effective therapies.
- Open Access
- 27 January 2025
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 14 (1) , 1-47
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics
Telomeres and telomerase play crucial roles in the initiation and progression of cancer. As biomarkers, they aid in distinguishing benign from malignant tissues. Despite the promising therapeutic potential of targeting telomeres and telomerase for therapy, translating this concept from the laboratory to the clinic remains challenging. Many candidate drugs remain in the experimental stage, with only a few advancing to clinical trials. This review explores the relationship between telomeres, telomerase, and cancer, synthesizing their roles as biomarkers and reviewing the outcomes of completed trials. We propose that changes in telomere length and telomerase activity can be used to stratify cancer stages. Furthermore, we suggest that differential expression of telomere and telomerase components at the subcellular level holds promise as a biomarker. From a therapeutic standpoint, combining telomerase-targeted therapies with drugs that mitigate the adverse effects of telomerase inhibition may offer a viable strategy.
- 27 January 2025
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 14 (1) , 1-47
Open AccessTelomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics
Telomeres and telomerase play crucial roles in the initiation and progression of cancer. As biomarkers, they aid in distinguishing benign from malignant tissues. Despite the promising therapeutic potential of targeting telomeres and telomerase for therapy, translating this concept from the laboratory to the clinic remains challenging. Many candidate drugs remain in the experimental stage, with only a few advancing to clinical trials. This review explores the relationship between telomeres, telomerase, and cancer, synthesizing their roles as biomarkers and reviewing the outcomes of completed trials. We propose that changes in telomere length and telomerase activity can be used to stratify cancer stages. Furthermore, we suggest that differential expression of telomere and telomerase components at the subcellular level holds promise as a biomarker. From a therapeutic standpoint, combining telomerase-targeted therapies with drugs that mitigate the adverse effects of telomerase inhibition may offer a viable strategy.
- Open Access
- 21 January 2025
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 12 (1) , e001544
Current and projected incidence rates of pancreatic cancer in 43 countries: an analysis of the Cancer Incidence in Five Continents database
Objective The aetiology of pancreatic cancer is complex, and there is limited research on its incidence. We aimed to investigate the incidence trends of pancreatic cancer in 43 countries and predict trends up to 2030. Methods The annual incidence of pancreatic cancer was obtained from the Cancer Incidence in Five Continents database, which comprises 108 cancer registries from 43 countries. Based on available data, we calculated age-standardized incidence rates (ASRs) per 100 000 people for 1988–2012. A Bayesian age-period-cohort model was used to predict the number of new cases and incidence rates up to 2030. Results From 1988 to 2012, the global incidence rate of pancreatic cancer showed a continuously increasing trend, with the ASR increasing from 5.89 in 1988 to 6.78 in 2012, representing an overall average annual percentage change of 8.45%. This increasing trend is expected to persist in most selected countries, whereas a few countries are projected to exhibit a declining trend by 2030. Conclusion It appears that the future global incidence of pancreatic cancer is on the rise, but the rate of increase varies among different countries, with some showing a declining trend.
- 21 January 2025
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 12 (1) , e001544
Open AccessCurrent and projected incidence rates of pancreatic cancer in 43 countries: an analysis of the Cancer Incidence in Five Continents database
Objective The aetiology of pancreatic cancer is complex, and there is limited research on its incidence. We aimed to investigate the incidence trends of pancreatic cancer in 43 countries and predict trends up to 2030. Methods The annual incidence of pancreatic cancer was obtained from the Cancer Incidence in Five Continents database, which comprises 108 cancer registries from 43 countries. Based on available data, we calculated age-standardized incidence rates (ASRs) per 100 000 people for 1988–2012. A Bayesian age-period-cohort model was used to predict the number of new cases and incidence rates up to 2030. Results From 1988 to 2012, the global incidence rate of pancreatic cancer showed a continuously increasing trend, with the ASR increasing from 5.89 in 1988 to 6.78 in 2012, representing an overall average annual percentage change of 8.45%. This increasing trend is expected to persist in most selected countries, whereas a few countries are projected to exhibit a declining trend by 2030. Conclusion It appears that the future global incidence of pancreatic cancer is on the rise, but the rate of increase varies among different countries, with some showing a declining trend.
- Open Access
- 17 December 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 322, 117590
Bioinformatics analyses of infiltrating immune cell participation on pancreatic ductal adenocarcinoma progression and in vivo experiment of the therapeutic effect of Shuangshen granules
- 17 December 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 322, 117590
Open AccessBioinformatics analyses of infiltrating immune cell participation on pancreatic ductal adenocarcinoma progression and in vivo experiment of the therapeutic effect of Shuangshen granules
- Open Access
- 19 August 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (33) , e30103
Single ultrasound-guided local high-dose thrombin injection in the treatment of giant brachial artery pseudoaneurysm: A case report
Rationale: Pseudoaneurysm (PSA) is a common complication related to vascular intervention, and surgical therapy is the primary method. However, a giant brachial artery PSA over 2 weeks is rarely observed. Due to the adhesion of surrounding tissue, thrombus organization, the extensive injury, and the high expense of transluminal stent-graft placement, a single ultrasound-guided local high-dose thrombin injection can be a therapy option. Such cases are rarely reported. Patient concerns: A 71-year-old man with a history of left elbow fossa interventional puncture presented to our hospital with a pulsatile mass in the left elbow fossa. He had a history of cerebral infarction 32 years prior without sequelae, emphysema for more than 2 years, hyperlipidemia for 3 months, and prostatic hyperplasia for 8 months. After conservative therapy, the lumbar compression fracture produced by trauma 24 years ago healed, and the intracranial hematoma induced by trauma ten years ago was absorbed. Diagnosis: Ultrasound examination showed giant mixed echoes on the posterior medial side of the left brachial artery. Interventions: The patient underwent a single ultrasound-guided local high-dose thrombin injection to treat giant brachial artery PSA. Outcomes: Following therapy, the ultrasonography revealed that extensive thrombosis immediately formed in the cavity, and the internal blood flow signals had completely vanished. A week later, a physical examination showed that the PSA had shrunk with no apparent tenderness and that the texture had hardened. Pulsation and vascular murmurs disappeared. Ultrasound showed that the PSA was reduced, and no blood flow signals were found. Lessons: A single ultrasound-guided local high-dose thrombin injection had a considerable effect in curing large iatrogenic PSA. However, when deciding on the best therapy, specificity must be taken into account.
- 19 August 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (33) , e30103
Open AccessSingle ultrasound-guided local high-dose thrombin injection in the treatment of giant brachial artery pseudoaneurysm: A case report
Rationale: Pseudoaneurysm (PSA) is a common complication related to vascular intervention, and surgical therapy is the primary method. However, a giant brachial artery PSA over 2 weeks is rarely observed. Due to the adhesion of surrounding tissue, thrombus organization, the extensive injury, and the high expense of transluminal stent-graft placement, a single ultrasound-guided local high-dose thrombin injection can be a therapy option. Such cases are rarely reported. Patient concerns: A 71-year-old man with a history of left elbow fossa interventional puncture presented to our hospital with a pulsatile mass in the left elbow fossa. He had a history of cerebral infarction 32 years prior without sequelae, emphysema for more than 2 years, hyperlipidemia for 3 months, and prostatic hyperplasia for 8 months. After conservative therapy, the lumbar compression fracture produced by trauma 24 years ago healed, and the intracranial hematoma induced by trauma ten years ago was absorbed. Diagnosis: Ultrasound examination showed giant mixed echoes on the posterior medial side of the left brachial artery. Interventions: The patient underwent a single ultrasound-guided local high-dose thrombin injection to treat giant brachial artery PSA. Outcomes: Following therapy, the ultrasonography revealed that extensive thrombosis immediately formed in the cavity, and the internal blood flow signals had completely vanished. A week later, a physical examination showed that the PSA had shrunk with no apparent tenderness and that the texture had hardened. Pulsation and vascular murmurs disappeared. Ultrasound showed that the PSA was reduced, and no blood flow signals were found. Lessons: A single ultrasound-guided local high-dose thrombin injection had a considerable effect in curing large iatrogenic PSA. However, when deciding on the best therapy, specificity must be taken into account.
- 29 July 2022
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 33 (8) , e812-e814
“Rapid Formation, Acute Rupture” Course of Intracranial Aneurysm
Intracranial aneurysm (IA) is a devastating cerebrovascular disease characterizing with a potential rupturing risk. In previous studies, the formation of IA was considered to be in a chronic manner, and the ruptured aneurysms might merely derived from the already formed unruptured IA. A 61-year-old male presented to the hospital complaining of a headache. The patient received neuroimage tests, including head computed tomography and digital substraction angiography, to examine the underlying cerebrovascular diseases. Interestingly, we found a newborn ruptured IA with 9-day intervals between 2 whole-cerebral digital subtraction angiography examinations. In summary, the case in our report provides a clue for the natural course that the IA is probably in a “rapid formation, acute rupture” manner.
- 29 July 2022
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 33 (8) , e812-e814
“Rapid Formation, Acute Rupture” Course of Intracranial Aneurysm
Intracranial aneurysm (IA) is a devastating cerebrovascular disease characterizing with a potential rupturing risk. In previous studies, the formation of IA was considered to be in a chronic manner, and the ruptured aneurysms might merely derived from the already formed unruptured IA. A 61-year-old male presented to the hospital complaining of a headache. The patient received neuroimage tests, including head computed tomography and digital substraction angiography, to examine the underlying cerebrovascular diseases. Interestingly, we found a newborn ruptured IA with 9-day intervals between 2 whole-cerebral digital subtraction angiography examinations. In summary, the case in our report provides a clue for the natural course that the IA is probably in a “rapid formation, acute rupture” manner.